Clinical Trials
ASCO 2026 Highlights: Landmark Clinical Data Points to Survival Extensions in Pancreatic and Lung Cancers
The annual ASCO conference has delivered landmark clinical trial results, bringing promising survival extensions for pancreatic cancer and targeted lung cancer therapies.
Clinical Trials
The 2026 Obesity Power Rankings: Which Pharma Giants Can Break the Lilly-Novo Duopoly?
With the obesity market projected to exceed $130 billion by 2034, we analyze the top 10 pharmaceutical companies vying for dominance. Explore our comprehensive Power Rankings assessing pipeline depth, clinical differentiation, and commercial infrastructure.
Clinical Trials
Helus Pharma Secures US$50M Offering as MDD Trial Surpasses 86% Enrollment
Helus Pharma announces a $50 million offering to progress Phase 3 trials for their novel serotonergic agonists, alongside major clinical milestones and leadership updates.
Clinical Trials
J-Pharma and Uniphar Advance Nanvuranlat into Global Phase III Trial for Biliary Tract Cancer
Japanese biotech J-Pharma and Ireland-based Uniphar have received FDA alignment to bypass Phase II and advance nanvuranlat (JPH203) directly into a pivotal global Phase III study for second-line biliary tract cancer.
Clinical Trials
Navigating Challenges in Oncology: Jazz Pharmaceuticals and PharmaMar Stay Committed Despite Phase 3 Setback
In the rigorous and highly demanding landscape of oncology research, scientific progress is often non-linear. Recently, Jazz Pharmaceuticals and its partner PharmaMar announced that their Phase 3 trial evaluating Zepzelca did not meet its primary endpoint.